AAPL338.32-6.31 (-1.83%) ▼|ABBV288.84-6.05 (-2.05%) ▼|ABT110.16+3.96 (+3.73%) ▲|ACN260.94+2.70 (+1.05%) ▲|ADBE251.47+1.24 (+0.50%) ▲|AMAT374.53-15.56 (-3.99%) ▼|AMD466.84-37.96 (-7.52%) ▼|AMGN465.45-0.56 (-0.12%) ▼|AMT188.30+0.52 (+0.28%) ▲|AMZN245.63+5.28 (+2.20%) ▲|AVGO322.23-3.85 (-1.18%) ▼|AXP327.98+8.87 (+2.78%) ▲|BA175.40+3.85 (+2.24%) ▲|BAC49.57-0.44 (-0.88%) ▼|BKNG153.75+5.62 (+3.79%) ▲|BLK1,167.15+19.61 (+1.71%) ▲|BMY63.02+0.54 (+0.86%) ▲|BNY147.78+0.67 (+0.46%) ▲|BRK-B556.11+13.62 (+2.51%) ▲|C123.10+1.13 (+0.93%) ▲|CAT613.62-9.13 (-1.47%) ▼|CL97.43+2.14 (+2.25%) ▲|CMCSA23.87+0.65 (+2.80%) ▲|COF210.77+5.92 (+2.89%) ▲|COP146.84-7.19 (-4.67%) ▼|COST1,040.55+28.27 (+2.79%) ▲|CRM226.18-2.99 (-1.30%) ▼|CSCO101.61-2.90 (-2.77%) ▼|CVS88.51-1.74 (-1.93%) ▼|CVX227.77-7.75 (-3.29%) ▼|DE667.60-7.88 (-1.17%) ▼|DHR227.97-4.26 (-1.83%) ▼|DIS113.11+2.17 (+1.96%) ▲|DUK128.38+0.99 (+0.78%) ▲|EMR165.96+1.02 (+0.62%) ▲|FDX318.25+4.97 (+1.59%) ▲|GD373.46+0.87 (+0.23%) ▲|GE315.78+13.98 (+4.63%) ▲|GEV862.25+4.38 (+0.51%) ▲|GILD170.33-0.35 (-0.21%) ▼|GM89.94+2.54 (+2.91%) ▲|GOOG278.04-0.18 (-0.06%) ▼|GOOGL278.99-0.85 (-0.30%) ▼|GS898.72+4.17 (+0.47%) ▲|HD341.15+11.95 (+3.63%) ▲|HON223.77+5.44 (+2.49%) ▲|IBM252.51-5.30 (-2.06%) ▼|INTC59.97-5.79 (-8.80%) ▼|INTU352.10+11.01 (+3.23%) ▲|ISRG436.87+4.86 (+1.13%) ▲|JNJ270.56-2.64 (-0.97%) ▼|JPM340.58+3.54 (+1.05%) ▲|KO95.83+1.75 (+1.86%) ▲|LIN519.72+5.48 (+1.07%) ▲|LLY1,410.99-6.55 (-0.46%) ▼|LMT643.15+6.20 (+0.97%) ▲|LOW218.15+9.08 (+4.34%) ▲|LRCX227.56-11.55 (-4.83%) ▼|MA658.10+20.09 (+3.15%) ▲|MCD265.64+7.52 (+2.91%) ▲|MDLZ66.38+1.44 (+2.22%) ▲|MDT99.29+2.75 (+2.85%) ▲|META606.73-8.26 (-1.34%) ▼|MMM178.36+4.02 (+2.31%) ▲|MO77.17-0.86 (-1.10%) ▼|MRK148.36-1.16 (-0.78%) ▼|MS185.73+1.43 (+0.78%) ▲|MSFT507.12-14.79 (-2.83%) ▼|MU833.59-51.15 (-5.78%) ▼|NEE85.03+1.32 (+1.58%) ▲|NFLX62.34+0.26 (+0.42%) ▲|NKE39.12+0.45 (+1.16%) ▲|NOW106.01+0.89 (+0.85%) ▲|NVDA202.06-2.58 (-1.26%) ▼|ORCL119.22-11.45 (-8.76%) ▼|PEP140.42+3.08 (+2.24%) ▲|PFE30.67+0.15 (+0.49%) ▲|PG163.56+1.99 (+1.23%) ▲|PLTR178.34-5.77 (-3.13%) ▼|PM208.29-0.50 (-0.24%) ▼|QCOM162.08-2.71 (-1.64%) ▼|RTX202.79+2.99 (+1.50%) ▲|SBUX104.40+0.75 (+0.72%) ▲|SCHW88.71+0.66 (+0.75%) ▲|SO94.61+0.90 (+0.96%) ▲|SPG221.73+3.98 (+1.83%) ▲|T21.44+0.03 (+0.14%) ▲|TMO682.65-14.35 (-2.06%) ▼|TMUS160.15+3.71 (+2.37%) ▲|TSLA403.82+4.01 (+1.00%) ▲|TXN302.02+1.18 (+0.39%) ▲|UBER66.71+1.46 (+2.24%) ▲|UNH400.44-6.53 (-1.60%) ▼|UNP307.00+3.00 (+0.99%) ▲|UPS109.71+1.46 (+1.35%) ▲|USB60.49+1.04 (+1.75%) ▲|V425.51+11.92 (+2.88%) ▲|VZ45.05+0.32 (+0.72%) ▲|WFC85.89+2.49 (+2.99%) ▲|WMT127.69+4.18 (+3.38%) ▲|XOM179.67-7.58 (-4.05%) ▼|AAPL338.32-6.31 (-1.83%) ▼|ABBV288.84-6.05 (-2.05%) ▼|ABT110.16+3.96 (+3.73%) ▲|ACN260.94+2.70 (+1.05%) ▲|ADBE251.47+1.24 (+0.50%) ▲|AMAT374.53-15.56 (-3.99%) ▼|AMD466.84-37.96 (-7.52%) ▼|AMGN465.45-0.56 (-0.12%) ▼|AMT188.30+0.52 (+0.28%) ▲|AMZN245.63+5.28 (+2.20%) ▲|AVGO322.23-3.85 (-1.18%) ▼|AXP327.98+8.87 (+2.78%) ▲|BA175.40+3.85 (+2.24%) ▲|BAC49.57-0.44 (-0.88%) ▼|BKNG153.75+5.62 (+3.79%) ▲|BLK1,167.15+19.61 (+1.71%) ▲|BMY63.02+0.54 (+0.86%) ▲|BNY147.78+0.67 (+0.46%) ▲|BRK-B556.11+13.62 (+2.51%) ▲|C123.10+1.13 (+0.93%) ▲|CAT613.62-9.13 (-1.47%) ▼|CL97.43+2.14 (+2.25%) ▲|CMCSA23.87+0.65 (+2.80%) ▲|COF210.77+5.92 (+2.89%) ▲|COP146.84-7.19 (-4.67%) ▼|COST1,040.55+28.27 (+2.79%) ▲|CRM226.18-2.99 (-1.30%) ▼|CSCO101.61-2.90 (-2.77%) ▼|CVS88.51-1.74 (-1.93%) ▼|CVX227.77-7.75 (-3.29%) ▼|DE667.60-7.88 (-1.17%) ▼|DHR227.97-4.26 (-1.83%) ▼|DIS113.11+2.17 (+1.96%) ▲|DUK128.38+0.99 (+0.78%) ▲|EMR165.96+1.02 (+0.62%) ▲|FDX318.25+4.97 (+1.59%) ▲|GD373.46+0.87 (+0.23%) ▲|GE315.78+13.98 (+4.63%) ▲|GEV862.25+4.38 (+0.51%) ▲|GILD170.33-0.35 (-0.21%) ▼|GM89.94+2.54 (+2.91%) ▲|GOOG278.04-0.18 (-0.06%) ▼|GOOGL278.99-0.85 (-0.30%) ▼|GS898.72+4.17 (+0.47%) ▲|HD341.15+11.95 (+3.63%) ▲|HON223.77+5.44 (+2.49%) ▲|IBM252.51-5.30 (-2.06%) ▼|INTC59.97-5.79 (-8.80%) ▼|INTU352.10+11.01 (+3.23%) ▲|ISRG436.87+4.86 (+1.13%) ▲|JNJ270.56-2.64 (-0.97%) ▼|JPM340.58+3.54 (+1.05%) ▲|KO95.83+1.75 (+1.86%) ▲|LIN519.72+5.48 (+1.07%) ▲|LLY1,410.99-6.55 (-0.46%) ▼|LMT643.15+6.20 (+0.97%) ▲|LOW218.15+9.08 (+4.34%) ▲|LRCX227.56-11.55 (-4.83%) ▼|MA658.10+20.09 (+3.15%) ▲|MCD265.64+7.52 (+2.91%) ▲|MDLZ66.38+1.44 (+2.22%) ▲|MDT99.29+2.75 (+2.85%) ▲|META606.73-8.26 (-1.34%) ▼|MMM178.36+4.02 (+2.31%) ▲|MO77.17-0.86 (-1.10%) ▼|MRK148.36-1.16 (-0.78%) ▼|MS185.73+1.43 (+0.78%) ▲|MSFT507.12-14.79 (-2.83%) ▼|MU833.59-51.15 (-5.78%) ▼|NEE85.03+1.32 (+1.58%) ▲|NFLX62.34+0.26 (+0.42%) ▲|NKE39.12+0.45 (+1.16%) ▲|NOW106.01+0.89 (+0.85%) ▲|NVDA202.06-2.58 (-1.26%) ▼|ORCL119.22-11.45 (-8.76%) ▼|PEP140.42+3.08 (+2.24%) ▲|PFE30.67+0.15 (+0.49%) ▲|PG163.56+1.99 (+1.23%) ▲|PLTR178.34-5.77 (-3.13%) ▼|PM208.29-0.50 (-0.24%) ▼|QCOM162.08-2.71 (-1.64%) ▼|RTX202.79+2.99 (+1.50%) ▲|SBUX104.40+0.75 (+0.72%) ▲|SCHW88.71+0.66 (+0.75%) ▲|SO94.61+0.90 (+0.96%) ▲|SPG221.73+3.98 (+1.83%) ▲|T21.44+0.03 (+0.14%) ▲|TMO682.65-14.35 (-2.06%) ▼|TMUS160.15+3.71 (+2.37%) ▲|TSLA403.82+4.01 (+1.00%) ▲|TXN302.02+1.18 (+0.39%) ▲|UBER66.71+1.46 (+2.24%) ▲|UNH400.44-6.53 (-1.60%) ▼|UNP307.00+3.00 (+0.99%) ▲|UPS109.71+1.46 (+1.35%) ▲|USB60.49+1.04 (+1.75%) ▲|V425.51+11.92 (+2.88%) ▲|VZ45.05+0.32 (+0.72%) ▲|WFC85.89+2.49 (+2.99%) ▲|WMT127.69+4.18 (+3.38%) ▲|XOM179.67-7.58 (-4.05%) ▼|
17.8 C
New York
Monday, November 2, 2026

Tag: operations

Mohawk Industries gibt Ergebnisse für das zweite Quartal 2025 bekannt

CALHOUN, Georgia, July 26, 2025 (GLOBE NEWSWIRE) -- Mohawk Industries, Inc. (NYSE: MHK) hat heute für das zweite Quartal 2025 einen Nettogewinn von 147 Millionen US-Dollar und einen Gewinn pro Aktie („EPS“) von 2,34 US-Dollar bekannt gegeben. Der bereinigte Nettogewinn belief sich auf 173 Millionen US-Dollar, der bereinigte Gewinn pro Aktie auf 2,77 US-Dollar. Der Nettoumsatz für das zweite Quartal 2025 belief sich auf 2,8 Milliarden US-Dollar, was im Wesentlichen dem ausgewiesenen Wert entspricht und bereinigt um konstante Tage und Wechselkurse gegenüber dem Vorjahr um 0,8 % zurückging. Im zweiten Quartal 2024 erzielte das Unternehmen einen Nettoumsatz von 2,8 Milliarden US-Dollar, einen Nettogewinn von 157 Millionen US-Dollar und einen Gewinn pro Aktie von 2,46 US-Dollar; der bereinigte Nettogewinn belief sich auf 192 Millionen US-Dollar und der bereinigte Gewinn pro Aktie auf 3,00 US-Dollar.

Mohawk Industries pubblica i risultati del secondo trimestre 2025

CALHOUN, Georgia, July 26, 2025 (GLOBE NEWSWIRE) -- Mohawk Industries, Inc. (NYSE: MHK) ha annunciato oggi un utile netto di 147 milioni di dollari e un utile per azione (“EPS”) di 2,34 dollari per il secondo trimestre 2025; l’utile netto rettificato è stato di 173 milioni di dollari e l’EPS rettificato di 2,77 dollari. Le vendite nette per il secondo trimestre del 2025 sono state di 2,8 miliardi di dollari, sostanzialmente invariato rispetto a quanto riportato e in calo dello 0,8% in base ai dati diffusi su base rettificata per i tassi di cambio e a giorni costanti rispetto all'anno precedente. Nel secondo trimestre del 2024, la Società aveva registrato vendite nette pari a 2,8 miliardi di dollari, un utile netto di 157 milioni di dollari e un utile per azione di 2,46 dollari; l’utile netto rettificato era di 192 milioni di dollari e l’EPS rettificato di 3,00 dollari.

Mohawk Industries 发布 2025 年第二季度财报

卡尔霍恩,佐治亚州, July 26, 2025 (GLOBE NEWSWIRE) -- Mohawk Industries, Inc. (NYSE: MHK) 今日宣布,公司 2025 年第二季度净收益为 1.47 亿美元,每股收益 (EPS) 为 2.34 美元;调整后净收益为 1.73 亿美元,调整后每股收益为 2.77 美元。 2025 年第二季度净销售额为 28 亿美元,按报告口径同比基本持平,按恒定工作日与汇率调整后同比下降 0.8%。 2024 年第二季度,公司报告净销售额 28 亿美元、净收益 1.57 亿美元、每股收益 2.46 美元;调整后净收益为 1.92 亿美元,调整后每股收益为 3.00 美元。

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates –

CHIPOTLE (CMG) ALERT: Bragar Eagel & Squire, P.C. Continues Investigating Chipotle Mexican Grill, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact...

If you purchased or acquired securities in Chipotle between February 8, 2024 to October 29, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Caribou (CRBU) To Contact Him Directly To Discuss Their Options

ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.

Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP) (OTCQB: RHEPA) (OTCQB: RHEPB), a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care, announced today that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) recommended that Regional shareholders vote “FOR”: (1) the approval of the Amended and Restated Agreement and Plan of Merger, dated April 14, 2025 (as amended, the “Merger Agreement”), by and between Regional and SunLink Health Systems, Inc. (the “Merger Proposal”), (2) the approval of the issuance of shares of Regional common stock and Regional Series D 8% Cumulative Convertible Redeemable Participating Preferred Shares (the “Regional Series D preferred stock”) in connection with the merger (the “Share Issuance Proposal”), and (3) the approval to adjourn the Regional special meeting to solicit additional proxies in favor of the Merger Proposal or the Share Issuance Proposal if there are insufficient votes at the time of such adjournment to approve the Merger Proposal or the Share Issuance Proposal.

ACADIA HEALTHCARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Healthcare Company, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact...

If you purchased or acquired stock in Acadia between February 28, 2020 to October 30, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

ATKORE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Atkore Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Atkore (ATKR)To Contact Him Directly To Discuss Their Options

BIRKS GROUP INC. REPORTS FISCAL 2025 RESULTS

MONTREAL, July 25, 2025 /CNW/ - Birks Group Inc. (the "Company" or "Birks Group") (NYSE American: BGI), today reported its financial results for the...

First Capital, Inc. Reports Quarterly Earnings

CORYDON, Ind., July 25, 2025 (GLOBE NEWSWIRE) -- First Capital, Inc. (the “Company”) (NASDAQ: FCAP), the holding company for First Harrison Bank (the “Bank”), today reported net income of $3.8 million, or $1.13 per diluted share, for the quarter ended June 30, 2025, compared to net income of $2.8 million, or $0.85 per diluted share, for the quarter ended June 30, 2024.

Paramount and Skydance Announce Anticipated Closing Date, Deadlines to Elect Merger Consideration and Change of Ticker Symbol Effective at the Closing

NEW YORK, July 25, 2025 /PRNewswire/ -- Paramount Global (NASDAQ: PARA, PARAA) ("Paramount") and Skydance Media, LLC ("Skydance") today announced that the transactions (the...

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsOperations